Brought to you by:
‘Why vascular?’: Grappling with the vascular workforce challenges of the future
It’s one of the enduring reasons given cross-generationally in answer to the question, “Why vascular?” It goes something along the lines of, “I value that vascular surgeons have longitudinal relationships with their patients.” That was the message from Jessica Simons,…
MDR certification secured for Impede embolization plug devices
Shape Memory Medical announced that its Impede embolization plug product family has received certification as a Class III device under the European Union (EU) Medical Device Regulation (MDR) 2017 The Impede devices, previously CE-marked under the Medical Device Directive 93/42/EEC…
SCVS Young Vascular Surgeons Program deadline further extended
The deadline for applications to the 2026 Society for Clinical Vascular Surgery (SCVS) Young Vascular Surgeons Program has been further extended to Jan. 4 at 11:59 p.m. Eastern Time. Designed for early-career vascular surgeons who have completed fellowships or an…
Interim results of covered stent-graft hint at ‘new avenue’ in dialysis access treatment
The interim results of a first-in-human trial of a sirolimus-eluting covered stent graft—Solaris DE (Solaris Endovascular)—for the treatment of dialysis access dysfunction demonstrate the promise of the device in treating vascular access outflow stenosis, an investigator in the trial has…
New era beckons: Vascular Specialist moves in-house as new chapter opens for SVS official newspaper
Malachi Sheahan III, MD, has been at the helm of Vascular Specialist for more than seven years. In that time, it is fair to say the newspaper—the official voice of the Society for Vascular Surgery (SVS)—has evolved. About a year…
Care for intermittent claudication considered ‘inappropriate’ found to be common, putting patients at ‘increased’ risk
In a multi-institutional cohort of patients with intermittent claudication (IC), care deemed inappropriate, or where the risk outweighs the benefit, by the SVS appropriate use criteria (AUC) for the management of IC was “common” and associated with increased risk of…
PERT, AI and the rise of thrombectomy devices: ‘PERT leads to more advanced thrombectomy removal therapies, lower hospital stays’
The increasing sophistication of the device space for the treatment of pulmonary embolism (PE) aligned with advances in the deployment of pulmonary embolism response teams (PERTs) are among factors leading to notable improvements in care, according to leading vascular surgeon…
Early-bird deadline for SAVS 2026 approaches
The early-bird deadline for registration at the 2026 Southern Association for Vascular Surgery (SAVS) annual meeting in Paradise Island, the Bahamas (Jan. 21–24) falls tomorrow (Dec. 13). SAVS organizers are encouraging those planning to attend to sign up before the…
Deadline extended for SCVS Young Surgeons Program
The application deadline for the Society for Clinical Vascular Surgery (SCVS) 2026 Young Vascular Surgeons Program has been extended until midnight Eastern Time on Sunday (Dec. 14). The program will take place as part of the 2026 SCVS Annual Symposium…
Medtronic announces first commercial use of Liberant thrombectomy system
Medtronic has announced the first commercial use of its Liberant thrombectomy system, which is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems. Medtronic notes that Liberant expands the…